PRDM9 and neoplasm: miR-101 and miR-26a can downregulate histone methyltransferase EZH2, reducing H3K27me3 levels and reactivating the transcription of tumor suppressor genes, thereby enhancing T cell activation and anti-tumor immune responses (229, 230).